Filed with ASX · · 23 pages · English and French
Proteomics International Laboratories Ltd. has released an investor webinar presentation outlining its commercial strategy and growth plans. The company has secured a distribution partnership with Healius and is rolling out its Promarker tests nationally, with further launches planned for the near future. A share purchase plan has been initiated to raise funds for these initiatives, targeting operational support through the upcoming years.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Proteomics International Laboratories Ltd Investor Webinar Disciplined Path to Commercial Success 4 November 2026 ASX: PIQ | ACN: 169 979 971 | Perth, Western Australia Disclaimer Disclaimer This presentation has been prepared by, and is the sole responsibility of Proteomics International...
Proteomics International Laboratories Ltd. on 6ix
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories